Approval was based on positive results from the Phase III balance study, where Tryngolza demonstrated a notable placebo-adjusted triglyceride reduction at 12 months.
FDA Approves Ionis Pharmaceuticals’ Tryngolza for Familial Chylomicronemia Syndrome